haloperidol has been researched along with Parkinsonian Disorders in 74 studies
Haloperidol: A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279)
haloperidol : A compound composed of a central piperidine structure with hydroxy and p-chlorophenyl substituents at position 4 and an N-linked p-fluorobutyrophenone moiety.
Parkinsonian Disorders: A group of disorders which feature impaired motor control characterized by bradykinesia, MUSCLE RIGIDITY; TREMOR; and postural instability. Parkinsonian diseases are generally divided into primary parkinsonism (see PARKINSON DISEASE), secondary parkinsonism (see PARKINSON DISEASE, SECONDARY) and inherited forms. These conditions are associated with dysfunction of dopaminergic or closely related motor integration neuronal pathways in the BASAL GANGLIA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Asenapine is approved by the Food and Drugs Administration in adults for acute treatment of schizophrenia or of manic or mixed episodes associated with bipolar I disorder with or without psychotic features." | 9.14 | Efficacy and safety of asenapine in a placebo- and haloperidol-controlled trial in patients with acute exacerbation of schizophrenia. ( Alphs, L; Cohen, M; Kane, JM; Panagides, J; Zhao, J, 2010) |
| "To evaluate the clinical effects of haloperidol for the management of schizophrenia and other similar serious mental illnesses compared with placebo." | 8.89 | Haloperidol versus placebo for schizophrenia. ( Adams, CE; Bergman, H; Irving, CB; Lawrie, S, 2013) |
| "This study used electromyography to describe tremulous jaw movement generated by bilateral electrolytic lesion in the VLS and compare it to tremors induced using subchronic IP treatment with haloperidol, a dopaminergic D2 receptor antagonist." | 7.80 | Induction of mandibular tremor using electrolytic lesion of the ventrolateral striatum or using subchronic haloperidol therapy in male rats: an electromyographic comparison. ( García, LI; Hernández, ME; Herrera-Meza, G; Manzo, J; Miquel, M, 2014) |
| "Adenosine and its analogues have been shown to induce "behavioral despair" in animal models believed to be relevant to depression." | 7.72 | Adenosine A2A receptors and depression. ( Costentin, J; El Yacoubi, M; Vaugeois, JM, 2003) |
| "Asenapine is approved by the Food and Drugs Administration in adults for acute treatment of schizophrenia or of manic or mixed episodes associated with bipolar I disorder with or without psychotic features." | 5.14 | Efficacy and safety of asenapine in a placebo- and haloperidol-controlled trial in patients with acute exacerbation of schizophrenia. ( Alphs, L; Cohen, M; Kane, JM; Panagides, J; Zhao, J, 2010) |
| "To evaluate the clinical effects of haloperidol for the management of schizophrenia and other similar serious mental illnesses compared with placebo." | 4.89 | Haloperidol versus placebo for schizophrenia. ( Adams, CE; Bergman, H; Irving, CB; Lawrie, S, 2013) |
| "This study used electromyography to describe tremulous jaw movement generated by bilateral electrolytic lesion in the VLS and compare it to tremors induced using subchronic IP treatment with haloperidol, a dopaminergic D2 receptor antagonist." | 3.80 | Induction of mandibular tremor using electrolytic lesion of the ventrolateral striatum or using subchronic haloperidol therapy in male rats: an electromyographic comparison. ( García, LI; Hernández, ME; Herrera-Meza, G; Manzo, J; Miquel, M, 2014) |
| "Adenosine and its analogues have been shown to induce "behavioral despair" in animal models believed to be relevant to depression." | 3.72 | Adenosine A2A receptors and depression. ( Costentin, J; El Yacoubi, M; Vaugeois, JM, 2003) |
| " Previous research has reported that haloperidol induces tremulous jaw movements that have many of the characteristics of parkinsonian tremor." | 3.72 | The adenosine A2A antagonist KF17837 reverses the locomotor suppression and tremulous jaw movements induced by haloperidol in rats: possible relevance to parkinsonism. ( Betz, A; Correa, M; Dobson, DR; O'Neill, MF; O'Neill, MJ; Salamone, JD; Wisniecki, A, 2004) |
| "The aim of the present study was to determine whether S-4-carboxy-3-hydroxyphenylglycine (S)-4C3HPG, a mixed group I glutamate metabotropic receptor antagonist and a group II agonist, attenuated parkinsonian-like muscle rigidity in rats." | 3.71 | (S)-4C3HPG, a mixed group I mGlu receptor antagonist and a group II agonist, administered intrastriatally, counteracts parkinsonian-like muscle rigidity in rats. ( Lorenc-Koci, E; Pilc, A; Wardas, J; Wolfarth, S, 2001) |
| "Several useful animal models for parkinsonism have been developed so far." | 2.72 | Haloperidol-induced catalepsy as an animal model for parkinsonism: A systematic review of experimental studies. ( Alves, CO; de Oliveira, AR; Magalhães, MS; Waku, I, 2021) |
| "Parkinsonism has a toxic cascade of neurodegeneration, with akinesia as a major manifestation." | 1.62 | Appraisal of Nano-Lipidic Astaxanthin cum Thermoreversible Gel and its Efficacy in Haloperidol Induced Parkinsonism. ( Gautam, D; Kushwaha, S; Maurya, P; Saraf, SA; Singh, M; Singh, S, 2021) |
| "Varenicline was administered daily, 30 min prior to the administration of haloperidol." | 1.48 | Haloperidol-induced parkinsonism is attenuated by varenicline in mice. ( Gupta, S; Patel, RK; Sharma, AK; Wardhan, N, 2018) |
| " Losartan carboxylic acid (LCA), the potent AT1 blocker metabolite of losartan, suffers from poor bioavailability and brain access." | 1.48 | Conjugation to Ascorbic Acid Enhances Brain Availability of Losartan Carboxylic Acid and Protects Against Parkinsonism in Rats. ( Prusty, S; Sahu, PK; Singh, VK; Subudhi, BB, 2018) |
| "Epigallocatechin gallate (EGCG) is a major component of tea and its known interactions with caffeine make it worthwhile to further study them by investigating the influence of EGCG on the anticataleptic and locomotor-sensitizing effects of caffeine." | 1.42 | Tea component, epigallocatechin gallate, potentiates anticataleptic and locomotor-sensitizing effects of caffeine in mice. ( Acquas, E; Arote, S; Cotti, E; Gaikar, M; Kasture, SB; Kasture, V; Rosas, M; Salve, B, 2015) |
| "The cause of Parkinsonism has been described as wide and elusive, however, environmental toxins and drugs accounts for large percentage of spontaneous cases in humans." | 1.42 | -NMDA R/+VDR pharmacological phenotype as a novel therapeutic target in relieving motor-cognitive impairments in Parkinsonism. ( Abdulbasit, A; Balogun, WG; Cobham, AE; Enye, LA; Ishola, AO; Nanakumo, ET; Obende, OM; Ogundele, OM, 2015) |
| "A significant reduction of the catalepsy response was seen in rats previously given haloperidol and receiving DBS at the IC." | 1.42 | Deep brain stimulation of the inferior colliculus: a possible animal model to study paradoxical kinesia observed in some parkinsonian patients? ( Melo-Thomas, L; Thomas, U, 2015) |
| "In order to assess whether caffeine and theophylline have the same potency and efficacy to reverse the impairment of motor function caused by acute or chronic interruption of striatal dopamine transmission, a comparison of their dose-response relationship was made in the acute model of haloperidol-induced catalepsy, and the chronic model of unilateral lesion of the dopamine nigrostriatal pathway with 6-hydroxydopamine." | 1.39 | Caffeine has greater potency and efficacy than theophylline to reverse the motor impairment caused by chronic but not acute interruption of striatal dopaminergic transmission in rats. ( Acuña-Lizama, MM; Alvarez-Cervera, FJ; Bata-García, JL; Góngora-Alfaro, JL, 2013) |
| "Antipsychotic-induced parkinsonism (AIP) is one of the most common adverse effects of haloperidol." | 1.38 | Quality of life of elderly patients with antipsychotic-induced parkinsonism: a cross-sectional study. ( Egberts, TC; Jansen, PA; Knol, W; Schobben, AF; Schouten, HJ; van Marum, RJ, 2012) |
| "3 mg/kg) produced a transient decrease of extracellular DA levels over 6 h and showed maximum PPX levels 2 h after dosing which decreased over the following 6-8 h." | 1.36 | Continuous dopaminergic stimulation by pramipexole is effective to treat early morning akinesia in animal models of Parkinson's disease: A pharmacokinetic-pharmacodynamic study using in vivo microdialysis in rats. ( Buck, K; Buerger, E; Ferger, B; Koros, E; Shimasaki, M; Voehringer, P, 2010) |
| "A large cohort of 1528 patients with parkinsonism was analyzed, gathering data on demography, motor and non-motor characteristics, as well as the final etiologic diagnoses based on established criteria." | 1.36 | The differential diagnoses of parkinsonism: findings from a cohort of 1528 patients and a 10 years comparison in tertiary movement disorders clinics. ( Munhoz, RP; Teive, HA; Werneck, LC, 2010) |
| " In contrast, acute or chronic administration of MPEP (mGlu5 receptor antagonist) has no anticataleptic action." | 1.35 | Functional interaction between adenosine A2A and group III metabotropic glutamate receptors to reduce parkinsonian symptoms in rats. ( Amalric, M; Brotchie, JM; Johnston, TH; Lopez, S; Neuville, P; Schann, S; Turle-Lorenzo, N, 2008) |
| "Haloperidol is a classical antipsychotic drug, which produces extra-pyrimidal Parkinson's symptoms (EPS)." | 1.35 | Antagonism of haloperidol-induced swim impairment in L-dopa and caffeine treated mice: a pre-clinical model to study Parkinson's disease. ( Barodia, SK; Luthra, PM; Raghubir, R, 2009) |
| "MTEP (3 and 5 mg/kg i." | 1.33 | MTEP, a new selective antagonist of the metabotropic glutamate receptor subtype 5 (mGluR5), produces antiparkinsonian-like effects in rats. ( Konieczny, J; Ossowska, K; Pilc, A; Wolfarth, S, 2005) |
| "Neuroleptic-induced catalepsy has long been used as an animal model for screening drugs for Parkinsonism." | 1.33 | Effect of BR-16A (Mentat), a polyherbal formulation on drug-induced catalepsy in mice. ( Kulkarni, SK; Kumar, A, 2006) |
| "Behaviour was evaluated by catalepsy tests and activity box." | 1.32 | Potentiation of parkinsonian symptoms by depletion of locus coeruleus noradrenaline in 6-hydroxydopamine-induced partial degeneration of substantia nigra in rats. ( Schmidt, WJ; Srinivasan, J, 2003) |
| "Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism." | 1.31 | Acute and chronic haloperidol treatments increase parkin mRNA levels in the rat brain. ( Gotoh, L; Hirano, M; Kawanami, N; Motomura, K; Nakahara, T; Ohta, E; Uchimura, H, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 10 (13.51) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 24 (32.43) | 29.6817 |
| 2010's | 33 (44.59) | 24.3611 |
| 2020's | 7 (9.46) | 2.80 |
| Authors | Studies |
|---|---|
| Maliyakkal, N | 1 |
| Saleem, U | 3 |
| Anwar, F | 3 |
| Shah, MA | 2 |
| Ahmad, B | 3 |
| Umer, F | 1 |
| Almoyad, MAA | 1 |
| Parambi, DGT | 1 |
| Beeran, AA | 1 |
| Nath, LR | 1 |
| Aleya, L | 1 |
| Mathew, B | 1 |
| Khan, UA | 1 |
| Saifi, Z | 1 |
| Bora, J | 1 |
| Warsi, MH | 1 |
| Abourehab, MAS | 1 |
| Jain, GK | 1 |
| Kesharwani, P | 1 |
| Ali, A | 1 |
| Bounds, HA | 1 |
| Poeta, DL | 1 |
| Klinge, PM | 1 |
| Burwell, RD | 1 |
| Nurmaganbetov, ZS | 1 |
| Arystan, LI | 1 |
| Muldaeva, GM | 1 |
| Haydargalieva, LS | 1 |
| Adekenov, SM | 1 |
| Kiselev, AV | 1 |
| Vedenkin, AS | 1 |
| Stovbun, IS | 1 |
| Sergienko, VI | 1 |
| Kalinina, TS | 1 |
| Barroso-Hernández, A | 1 |
| Ramírez-Higuera, A | 1 |
| Peña-Montes, C | 1 |
| Cortés-Ramírez, SA | 1 |
| Rodríguez-Dorantes, M | 1 |
| López-Franco, Ó | 1 |
| Oliart-Ros, RM | 1 |
| Sanawar, M | 1 |
| Nazir, S | 1 |
| Akhtar, MF | 2 |
| Ismail, T | 1 |
| Gull, Z | 1 |
| Saleem, A | 1 |
| Panichayupakaranant, P | 1 |
| Waku, I | 1 |
| Magalhães, MS | 1 |
| Alves, CO | 1 |
| de Oliveira, AR | 1 |
| Gautam, D | 1 |
| Singh, S | 1 |
| Maurya, P | 1 |
| Singh, M | 1 |
| Kushwaha, S | 1 |
| Saraf, SA | 1 |
| Celorrio, M | 1 |
| Rojo-Bustamante, E | 1 |
| Fernández-Suárez, D | 1 |
| Sáez, E | 1 |
| Estella-Hermoso de Mendoza, A | 1 |
| Müller, CE | 1 |
| Ramírez, MJ | 1 |
| Oyarzábal, J | 1 |
| Franco, R | 1 |
| Aymerich, MS | 1 |
| Sharma, AK | 1 |
| Gupta, S | 1 |
| Patel, RK | 1 |
| Wardhan, N | 1 |
| Subudhi, BB | 1 |
| Sahu, PK | 1 |
| Singh, VK | 1 |
| Prusty, S | 1 |
| Knol, W | 3 |
| van Marum, RJ | 3 |
| Jansen, PA | 3 |
| Strengman, E | 1 |
| Al Hadithy, AF | 1 |
| Wilffert, B | 1 |
| Schobben, AF | 3 |
| Ophoff, RA | 1 |
| Egberts, TC | 3 |
| Adams, CE | 1 |
| Bergman, H | 1 |
| Irving, CB | 1 |
| Lawrie, S | 1 |
| Herrera-Meza, G | 1 |
| Manzo, J | 1 |
| Hernández, ME | 1 |
| Miquel, M | 1 |
| García, LI | 1 |
| Gubellini, P | 2 |
| Melon, C | 1 |
| Dale, E | 1 |
| Doller, D | 1 |
| Kerkerian-Le Goff, L | 1 |
| Zheng, J | 2 |
| Yang, Z | 2 |
| Li, X | 1 |
| Li, L | 2 |
| Ma, H | 2 |
| Wang, M | 1 |
| Zhang, H | 2 |
| Zhen, X | 2 |
| Zhang, X | 2 |
| Kasture, SB | 1 |
| Gaikar, M | 1 |
| Kasture, V | 1 |
| Arote, S | 1 |
| Salve, B | 1 |
| Rosas, M | 1 |
| Cotti, E | 1 |
| Acquas, E | 1 |
| Dekundy, A | 1 |
| Mela, F | 1 |
| Hofmann, M | 1 |
| Danysz, W | 1 |
| Ogundele, OM | 1 |
| Nanakumo, ET | 1 |
| Ishola, AO | 1 |
| Obende, OM | 1 |
| Enye, LA | 1 |
| Balogun, WG | 1 |
| Cobham, AE | 1 |
| Abdulbasit, A | 1 |
| Melo-Thomas, L | 1 |
| Thomas, U | 1 |
| Cannella, M | 1 |
| Motolese, M | 1 |
| Bucci, D | 1 |
| Molinaro, G | 1 |
| Gradini, R | 1 |
| Bruno, V | 1 |
| Nicoletti, F | 1 |
| Battaglia, G | 1 |
| Iderberg, H | 1 |
| Maslava, N | 1 |
| Thompson, AD | 1 |
| Bubser, M | 2 |
| Niswender, CM | 2 |
| Hopkins, CR | 1 |
| Lindsley, CW | 1 |
| Conn, PJ | 2 |
| Jones, CK | 2 |
| Cenci, MA | 1 |
| Stasi, MA | 1 |
| Minetti, P | 1 |
| Lombardo, K | 1 |
| Riccioni, T | 1 |
| Caprioli, A | 1 |
| Vertechy, M | 1 |
| Di Serio, S | 1 |
| Pace, S | 1 |
| Borsini, F | 1 |
| McConnell, GC | 1 |
| So, RQ | 1 |
| Grill, WM | 1 |
| Konieczny, J | 4 |
| Lenda, T | 1 |
| Czarnecka, A | 1 |
| Tian, S | 1 |
| Li, J | 1 |
| Lopez, S | 2 |
| Turle-Lorenzo, N | 1 |
| Johnston, TH | 1 |
| Brotchie, JM | 1 |
| Schann, S | 1 |
| Neuville, P | 1 |
| Amalric, M | 2 |
| Luthra, PM | 1 |
| Barodia, SK | 1 |
| Raghubir, R | 1 |
| Ciucci, MR | 1 |
| Ahrens, AM | 1 |
| Ma, ST | 1 |
| Kane, JR | 1 |
| Windham, EB | 1 |
| Woodlee, MT | 1 |
| Schallert, T | 1 |
| Beurrier, C | 1 |
| Révy, D | 1 |
| Selvam, C | 1 |
| Goudet, C | 1 |
| Lhérondel, M | 1 |
| Kerkerian-LeGoff, L | 1 |
| Acher, F | 1 |
| Pin, JP | 1 |
| Brown, AR | 1 |
| Hu, B | 1 |
| Antle, MC | 1 |
| Teskey, GC | 1 |
| Mabrouk, OS | 1 |
| Marti, M | 1 |
| Morari, M | 1 |
| Ferger, B | 1 |
| Buck, K | 1 |
| Shimasaki, M | 1 |
| Koros, E | 1 |
| Voehringer, P | 1 |
| Buerger, E | 1 |
| Munhoz, RP | 1 |
| Werneck, LC | 1 |
| Teive, HA | 1 |
| Kane, JM | 1 |
| Cohen, M | 1 |
| Zhao, J | 1 |
| Alphs, L | 1 |
| Panagides, J | 1 |
| Xue, Y | 1 |
| Chen, L | 1 |
| Schouten, HJ | 1 |
| Ardashov, OV | 1 |
| Pavlova, AV | 1 |
| Il'ina, IV | 1 |
| Morozova, EA | 1 |
| Korchagina, DV | 1 |
| Karpova, EV | 1 |
| Volcho, KP | 1 |
| Tolstikova, TG | 1 |
| Salakhutdinov, NF | 1 |
| Collins, LE | 1 |
| Sager, TN | 1 |
| Sams, AG | 1 |
| Pennarola, A | 1 |
| Port, RG | 1 |
| Shahriari, M | 1 |
| Salamone, JD | 2 |
| Povarnina, PY | 1 |
| Gudasheva, TA | 1 |
| Vorontsova, ON | 1 |
| Bondarenko, NA | 1 |
| Seredenin, SB | 1 |
| Johnson, KA | 1 |
| Tantawy, MN | 1 |
| Marvanova, M | 1 |
| Ansari, MS | 1 |
| Baldwin, RM | 1 |
| Acuña-Lizama, MM | 1 |
| Bata-García, JL | 1 |
| Alvarez-Cervera, FJ | 1 |
| Góngora-Alfaro, JL | 1 |
| Ohye, C | 1 |
| Shibazaki, T | 1 |
| Srinivasan, J | 1 |
| Schmidt, WJ | 3 |
| Gerstein, LM | 1 |
| Dovedova, EL | 1 |
| Popova, NS | 1 |
| COURT, JH | 1 |
| CAMERON, IA | 1 |
| SVENDSEN, BB | 1 |
| WILLADSEN, J | 1 |
| BROWN, AS | 1 |
| NEHLIL, J | 1 |
| ALLEVA, PM | 1 |
| GERLE, B | 1 |
| SABBATINI, F | 1 |
| JENSEN, K | 1 |
| AMDISEN, A | 1 |
| NAYRAC, P | 1 |
| ARNOTT, G | 1 |
| MILBLED, G | 1 |
| GEORGIADES, G | 1 |
| KYRATSOS, C | 1 |
| MICHAILIDES, G | 1 |
| TSINOPOULOS, T | 1 |
| Amtage, J | 1 |
| El Yacoubi, M | 1 |
| Costentin, J | 1 |
| Vaugeois, JM | 1 |
| Correa, M | 1 |
| Wisniecki, A | 1 |
| Betz, A | 1 |
| Dobson, DR | 1 |
| O'Neill, MF | 1 |
| O'Neill, MJ | 1 |
| Lebsanft, HB | 1 |
| Kohles, T | 1 |
| Kovar, KA | 1 |
| Ossowska, K | 2 |
| Wolfarth, S | 2 |
| Pilc, A | 3 |
| Kumar, A | 1 |
| Kulkarni, SK | 1 |
| White, C | 1 |
| McPherson, A | 1 |
| McCann, MA | 1 |
| Sadler, A | 1 |
| Fyvie, J | 1 |
| Wardas, J | 3 |
| Kuter, K | 1 |
| Meshul, CK | 1 |
| Allen, C | 1 |
| Lorenc-Koci, E | 2 |
| Nakahara, T | 1 |
| Gotoh, L | 1 |
| Motomura, K | 1 |
| Kawanami, N | 1 |
| Ohta, E | 1 |
| Hirano, M | 1 |
| Uchimura, H | 1 |
| Iwahashi, K | 1 |
| Anemo, K | 1 |
| Nakamura, K | 1 |
| Fukunishi, I | 1 |
| Igarashi, K | 1 |
| Rukoiatkina, NI | 1 |
| Gorbunova, LV | 1 |
| Gmiro, VE | 1 |
| Lukomskaia, NIa | 1 |
| Fernagut, PO | 1 |
| Diguet, E | 1 |
| Labattu, B | 1 |
| Tison, F | 1 |
| Klintenberg, R | 1 |
| Gunne, L | 1 |
| Andrén, PE | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| a Pilot Study of Pramipexole to Treat Extrapyramidal Symptoms Induced by Antipsychotics[NCT03430596] | Early Phase 1 | 50 participants (Actual) | Interventional | 2018-05-01 | Completed | ||
| A Multicenter, Randomized, Double-Blind, Fixed-Dose, 6-Week Trial of the Efficacy and Safety of Asenapine Compared With Placebo Using Haloperidol Positive Control in Subjects With an Acute Exacerbation of Schizophrenia[NCT00156104] | Phase 3 | 460 participants (Actual) | Interventional | 2005-07-01 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for haloperidol and Parkinsonian Disorders
| Article | Year |
|---|---|
Haloperidol-induced catalepsy as an animal model for parkinsonism: A systematic review of experimental studies.
Topics: Animals; Catalepsy; Disease Models, Animal; Haloperidol; Parkinsonian Disorders; Rats; Rats, Wistar | 2021 |
Haloperidol versus placebo for schizophrenia.
Topics: Akathisia, Drug-Induced; Antipsychotic Agents; Dystonia; Haloperidol; Humans; Parkinsonian Disorders | 2013 |
1 trial available for haloperidol and Parkinsonian Disorders
| Article | Year |
|---|---|
Efficacy and safety of asenapine in a placebo- and haloperidol-controlled trial in patients with acute exacerbation of schizophrenia.
Topics: Acute Disease; Adult; Akathisia, Drug-Induced; Dibenzocycloheptenes; Double-Blind Method; Female; Ha | 2010 |
71 other studies available for haloperidol and Parkinsonian Disorders
| Article | Year |
|---|---|
Ameliorative effect of ethoxylated chalcone-based MAO-B inhibitor on behavioural predictors of haloperidol-induced Parkinsonism in mice: evidence of its antioxidative role against Parkinson's diseases.
Topics: Animals; Antioxidants; Chalcones; Haloperidol; Mice; Monoamine Oxidase; Monoamine Oxidase Inhibitors | 2022 |
Intranasal inorganic cerium oxide nanoparticles ameliorate oxidative stress induced motor manifestations in haloperidol-induced parkinsonism.
Topics: Animals; Haloperidol; Nanoparticles; Oxidative Stress; Parkinsonian Disorders; Rats | 2023 |
Paw-Print Analysis of Contrast-Enhanced Recordings (PrAnCER): A Low-Cost, Open-Access Automated Gait Analysis System for Assessing Motor Deficits.
Topics: Animals; Cost-Benefit Analysis; Gait; Gait Analysis; Haloperidol; Male; Motor Disorders; Parkinsonia | 2019 |
Experimental study of antiparkinsonian action of the harmine hydrochloride original compound.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Catalepsy; Haloperidol; | 2019 |
Calcium Salt of N-(5-Hydroxynicotinoyl)-L-Glutamic Acid Weakens Depressive-Like Behavior and Parkinsonian Syndrome in Experiment on Rodents.
Topics: Animals; Antidepressive Agents; Calcium; Catalepsy; Depression; Glutamic Acid; Haloperidol; Male; Mi | 2019 |
Beneficial effects of an algal oil rich in ω-3 polyunsaturated fatty acids on locomotor function and D
Topics: Animals; Dopamine; Fatty Acids, Omega-3; Haloperidol; Humans; Parkinsonian Disorders; Rats; Rats, Wi | 2022 |
Investigation of anti-Parkinson activity of dicyclomine.
Topics: Animals; Dicyclomine; Disease Models, Animal; Dopamine; Haloperidol; Mice; Paraquat; Parkinson Disea | 2022 |
Appraisal of anti-Parkinson activity of rhinacanthin-C in haloperidol-induced parkinsonism in mice: A mechanistic approach.
Topics: Acanthaceae; Animals; Haloperidol; Mice; Naphthoquinones; Parkinsonian Disorders | 2021 |
Appraisal of Nano-Lipidic Astaxanthin cum Thermoreversible Gel and its Efficacy in Haloperidol Induced Parkinsonism.
Topics: Animals; Drug Carriers; Haloperidol; Lipids; Nanostructures; Parkinsonian Disorders; Particle Size; | 2021 |
GPR55: A therapeutic target for Parkinson's disease?
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Antiparkinson | 2017 |
Haloperidol-induced parkinsonism is attenuated by varenicline in mice.
Topics: Animals; Catalepsy; Disease Models, Animal; Dopamine; Female; Haloperidol; Levodopa; Male; Mice; Neu | 2018 |
Conjugation to Ascorbic Acid Enhances Brain Availability of Losartan Carboxylic Acid and Protects Against Parkinsonism in Rats.
Topics: Administration, Oral; Angiotensin II Type 1 Receptor Blockers; Animals; Ascorbic Acid; Behavior, Ani | 2018 |
Genetic variation and the risk of haloperidol-related parkinsonism in elderly patients: a candidate gene approach.
Topics: Aged; Aged, 80 and over; Alleles; Antipsychotic Agents; Cross-Sectional Studies; Female; Gene Freque | 2013 |
Induction of mandibular tremor using electrolytic lesion of the ventrolateral striatum or using subchronic haloperidol therapy in male rats: an electromyographic comparison.
Topics: Animals; Disease Models, Animal; Dopamine Antagonists; Electromyography; Haloperidol; Jaw; Male; Mot | 2014 |
Distinct effects of mGlu4 receptor positive allosteric modulators at corticostriatal vs. striatopallidal synapses may differentially contribute to their antiparkinsonian action.
Topics: Amino Acid Transport System X-AG; Anilides; Animals; Antiparkinson Agents; Brain; Cerebral Cortex; C | 2014 |
Optimization of 6-heterocyclic-2-(1H-pyrazol-1-yl)-N-(pyridin-2-yl)pyrimidin-4-amine as potent adenosine A2A receptor antagonists for the treatment of Parkinson's disease.
Topics: Adenosine A2 Receptor Antagonists; Animals; Antiparkinson Agents; Brain; Catalepsy; Dose-Response Re | 2014 |
Tea component, epigallocatechin gallate, potentiates anticataleptic and locomotor-sensitizing effects of caffeine in mice.
Topics: Animals; Antipsychotic Agents; Caffeine; Catalepsy; Catechin; Disease Models, Animal; Dose-Response | 2015 |
Effects of dopamine uptake inhibitor MRZ-9547 in animal models of Parkinson's disease.
Topics: Acetamides; Animals; Brain; Dopamine Uptake Inhibitors; Dose-Response Relationship, Drug; Drug Thera | 2015 |
-NMDA R/+VDR pharmacological phenotype as a novel therapeutic target in relieving motor-cognitive impairments in Parkinsonism.
Topics: Animals; Antiparkinson Agents; Brain; Calcium; Cognition Disorders; Disease Models, Animal; Disease | 2015 |
Deep brain stimulation of the inferior colliculus: a possible animal model to study paradoxical kinesia observed in some parkinsonian patients?
Topics: Animals; Catalepsy; Deep Brain Stimulation; Disease Models, Animal; Haloperidol; Inferior Colliculi; | 2015 |
Changes in the expression of genes encoding for mGlu4 and mGlu5 receptors and other regulators of the indirect pathway in acute mouse models of drug-induced parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Acute Disease; Animals; Catalepsy; Corpus Striatum; En | 2015 |
Pharmacological stimulation of metabotropic glutamate receptor type 4 in a rat model of Parkinson's disease and L-DOPA-induced dyskinesia: Comparison between a positive allosteric modulator and an orthosteric agonist.
Topics: Aminobutyrates; Animals; Antiparkinson Agents; Catalepsy; Dyskinesia, Drug-Induced; Excitatory Amino | 2015 |
Animal models of Parkinson׳s disease: Effects of two adenosine A2A receptor antagonists ST4206 and ST3932, metabolites of 2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine (ST1535).
Topics: Adenine; Adenosine A2 Receptor Antagonists; Administration, Oral; Animals; Antiparkinson Agents; Bas | 2015 |
Failure to suppress low-frequency neuronal oscillatory activity underlies the reduced effectiveness of random patterns of deep brain stimulation.
Topics: Action Potentials; Animals; Central Nervous System Stimulants; Deep Brain Stimulation; Dopamine D2 R | 2016 |
Early increase in dopamine release in the ipsilateral striatum after unilateral intranigral administration of lactacystin produces spontaneous contralateral rotations in rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Acetylcysteine; Amphetamine; Animals; Benzazepines; Central Nervous | 2016 |
Identification of a New Series of Potent Adenosine A
Topics: Adenosine A2 Receptor Antagonists; Animals; Antiparkinson Agents; Drug Design; Drug Evaluation, Prec | 2016 |
Functional interaction between adenosine A2A and group III metabotropic glutamate receptors to reduce parkinsonian symptoms in rats.
Topics: Adenosine A2 Receptor Antagonists; Animals; Behavior, Animal; Catalepsy; Cyclopentanes; Disease Mode | 2008 |
Antagonism of haloperidol-induced swim impairment in L-dopa and caffeine treated mice: a pre-clinical model to study Parkinson's disease.
Topics: Analysis of Variance; Animals; Antiparkinson Agents; Caffeine; Catalepsy; Corpus Striatum; Disease M | 2009 |
Reduction of dopamine synaptic activity: degradation of 50-kHz ultrasonic vocalization in rats.
Topics: Analysis of Variance; Animals; Chloroquinolinols; Corpus Striatum; Disease Models, Animal; Dopamine; | 2009 |
Electrophysiological and behavioral evidence that modulation of metabotropic glutamate receptor 4 with a new agonist reverses experimental parkinsonism.
Topics: Aminobutyrates; Animals; Antiparkinson Agents; Behavior; Catalepsy; Cell Line; Disease Models, Anima | 2009 |
Neocortical movement representations are reduced and reorganized following bilateral intrastriatal 6-hydroxydopamine infusion and dopamine type-2 receptor antagonism.
Topics: Animals; Corpus Striatum; Denervation; Disease Models, Animal; Dopamine; Dopamine Antagonists; Dopam | 2009 |
Endogenous nociceptin/orphanin FQ (N/OFQ) contributes to haloperidol-induced changes of nigral amino acid transmission and parkinsonism: a combined microdialysis and behavioral study in naïve and nociceptin/orphanin FQ receptor knockout mice.
Topics: Animals; Antipsychotic Agents; Benzimidazoles; Disease Models, Animal; Dose-Response Relationship, D | 2010 |
Continuous dopaminergic stimulation by pramipexole is effective to treat early morning akinesia in animal models of Parkinson's disease: A pharmacokinetic-pharmacodynamic study using in vivo microdialysis in rats.
Topics: Animals; Benzothiazoles; Catalepsy; Delayed-Action Preparations; Disease Models, Animal; Dopamine; D | 2010 |
The differential diagnoses of parkinsonism: findings from a cohort of 1528 patients and a 10 years comparison in tertiary movement disorders clinics.
Topics: Aged; Antipsychotic Agents; Cinnarizine; Cohort Studies; Diagnosis, Differential; Female; Flunarizin | 2010 |
Effects of pallidal neurotensin on haloperidol-induced parkinsonian catalepsy: behavioral and electrophysiological studies.
Topics: Animals; Antipsychotic Agents; Catalepsy; Disease Models, Animal; Dyskinesia, Drug-Induced; Globus P | 2010 |
Quality of life of elderly patients with antipsychotic-induced parkinsonism: a cross-sectional study.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Cross-Sectional Studies; Female; Haloperidol; Humans; | 2012 |
Highly potent activity of (1R,2R,6S)-3-methyl-6-(prop-1-en-2-yl)cyclohex-3-ene-1,2-diol in animal models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Cyclohexanols; Disease | 2011 |
The novel adenosine A2A antagonist Lu AA47070 reverses the motor and motivational effects produced by dopamine D2 receptor blockade.
Topics: Adenosine A2 Receptor Antagonists; Animals; Behavior, Animal; Choice Behavior; Depression; Dopamine | 2012 |
Antiparkinsonian properties of a nerve growth factor dipeptide mimetic GK-2 in in vivo experiments.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Catalepsy; Dipeptides; | 2011 |
The metabotropic glutamate receptor 8 agonist (S)-3,4-DCPG reverses motor deficits in prolonged but not acute models of Parkinson's disease.
Topics: Aminobutyrates; Animals; Benzoates; Catalepsy; Disease Models, Animal; Dopamine; Dopamine D2 Recepto | 2013 |
Parkinsonism in elderly users of haloperidol: associated with dose, plasma concentration, and duration of use.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Cross-Sectional Studies; Dose-Response Relationship, | 2012 |
Caffeine has greater potency and efficacy than theophylline to reverse the motor impairment caused by chronic but not acute interruption of striatal dopaminergic transmission in rats.
Topics: Animals; Caffeine; Catalepsy; Corpus Striatum; Dopaminergic Neurons; Dose-Response Relationship, Dru | 2013 |
Lesioning the thalamus for dyskinesia.
Topics: Antiparkinson Agents; Antipsychotic Agents; Dyskinesia, Drug-Induced; Dyskinesias; Electrocoagulatio | 2001 |
Potentiation of parkinsonian symptoms by depletion of locus coeruleus noradrenaline in 6-hydroxydopamine-induced partial degeneration of substantia nigra in rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic Agents; Animals; Behavior, Animal; Benzylamines; Cataleps | 2003 |
[Mechanism of nootropic digam action in hypofunction of brain dopaminergic system].
Topics: Animals; Caudate Nucleus; Dopamine Antagonists; GABA Agents; gamma-Aminobutyric Acid; Haloperidol; N | 2003 |
PSYCHOMOTOR ASSESSMENT OF THE EFFECTS OF HALOPERIDOL.
Topics: Bipolar Disorder; Haloperidol; Kinesthesis; Motor Skills; Parkinsonian Disorders; Psychotic Disorder | 1963 |
THE USE OF HALOPERIDOL (SERENASE (R)) IN CHLORPROTIXEN RESISTANT PATIENTS.
Topics: Accommodation, Ocular; Adolescent; Antisocial Personality Disorder; Bipolar Disorder; Chlorprothixen | 1963 |
NEUROLEPTANALGAESIA. THE PRESENT POSITION FOR NEUROSURGERY.
Topics: Adjuvants, Anesthesia; Analgesia; Anesthesia; Anesthesia, Intravenous; Haloperidol; Humans; Meperidi | 1963 |
[COMPLICATIONS OF NEUROLEPTICS].
Topics: Antipsychotic Agents; Chlorpromazine; Haloperidol; Parkinsonian Disorders; Phenothiazines; Prochlorp | 1963 |
[AKINETON IN PARKINSONISM CAUSED BY DRUGS].
Topics: Anti-Allergic Agents; Biperiden; Haloperidol; Histamine H1 Antagonists; Movement Disorders; Neurolog | 1963 |
[CLINICAL ASPECTS OF HALOPERIDOL].
Topics: Dementia; Geriatrics; Haloperidol; Injections, Intramuscular; Mental Disorders; Neurotic Disorders; | 1964 |
[THE NEUROTROPIC SIDE-EFFECTS OF BUTYRROPHENONES].
Topics: Haloperidol; Humans; Movement Disorders; Nervous System; Parkinsonian Disorders; Pharmacology; Toxic | 1964 |
TREATMENT OF DRUG-INDUCED PARKINSONISM: A COMPARISON BETWEEN UK-738, ORPHENADRINE, AND A PLACEBO IN A DOUBLE BLIND STUDY.
Topics: Clopenthixol; Double-Blind Method; Drug Therapy; Extrapyramidal Tracts; Haloperidol; Humans; Orphena | 1964 |
[HUNTINGTON'S CHOREA, HUMOR DISORDERS WITH MANIC MANIFESTATIONS, BENEFICIAL EFFECTS OF HALOPERIDOL (FLUOROPHENYLPIPERIDINOBUTYROPHENONE). ABSENCE OF THE THERAPEUTIC AKINETO-HYPERTONIC SYNDROME].
Topics: Bipolar Disorder; Chlorpromazine; Chorea; Electroencephalography; Electromyography; Haloperidol; Hum | 1964 |
[OCULAR PRESSURE, NEUROLEPTIC AGENTS AND PARKINSONIAN STATES].
Topics: Antipsychotic Agents; Chlorpromazine; Haloperidol; Intraocular Pressure; Methotrimeprazine; Parkinso | 1963 |
Context-dependent catalepsy intensification is due to classical conditioning and sensitization.
Topics: Animals; Association Learning; Cataplexy; Conditioning, Classical; Corpus Striatum; Dopamine; Dopami | 2003 |
Adenosine A2A receptors and depression.
Topics: Adenosine; Adenosine A2 Receptor Antagonists; Animals; Antidepressive Agents; Behavior, Animal; Caff | 2003 |
The adenosine A2A antagonist KF17837 reverses the locomotor suppression and tremulous jaw movements induced by haloperidol in rats: possible relevance to parkinsonism.
Topics: Adenosine A2 Receptor Antagonists; Animals; Behavior, Animal; Disease Models, Animal; Dose-Response | 2004 |
3,4-Methylenedioxymethamphetamine counteracts akinesia enantioselectively in rat rotational behavior and catalepsy.
Topics: Adrenergic Uptake Inhibitors; Animals; Antiparkinson Agents; Behavior, Animal; Catalepsy; Denervatio | 2005 |
MTEP, a new selective antagonist of the metabotropic glutamate receptor subtype 5 (mGluR5), produces antiparkinsonian-like effects in rats.
Topics: Animals; Antiparkinson Agents; Catalepsy; Disease Models, Animal; Dose-Response Relationship, Drug; | 2005 |
Effect of BR-16A (Mentat), a polyherbal formulation on drug-induced catalepsy in mice.
Topics: Animals; Catalepsy; Female; Haloperidol; Male; Medicine, Ayurvedic; Mice; Parkinsonian Disorders; Ph | 2006 |
Prolonged extra-pyramidal side effects after discontinuation of haloperidol as an antiemetic.
Topics: Aged; Antiemetics; Dopamine Antagonists; Female; Haloperidol; Humans; Nausea; Parkinsonian Disorders | 2006 |
The influence of group III metabotropic glutamate receptor stimulation by (1S,3R,4S)-1-aminocyclo-pentane-1,3,4-tricarboxylic acid on the parkinsonian-like akinesia and striatal proenkephalin and prodynorphin mRNA expression in rats.
Topics: Animals; Corpus Striatum; Cyclopentanes; Dopamine Antagonists; Dose-Response Relationship, Drug; Enk | 2007 |
Haloperidol reverses the changes in striatal glutamatergic immunolabeling following a 6-OHDA lesion.
Topics: Animals; Apomorphine; Denervation; Dopamine Agonists; Dopamine Antagonists; Glutamic Acid; Haloperid | 2000 |
(S)-4C3HPG, a mixed group I mGlu receptor antagonist and a group II agonist, administered intrastriatally, counteracts parkinsonian-like muscle rigidity in rats.
Topics: Animals; Anti-Dyskinesia Agents; Corpus Striatum; Disease Models, Animal; Electromyography; Glycine; | 2001 |
SCH 58261, an A(2A) adenosine receptor antagonist, counteracts parkinsonian-like muscle rigidity in rats.
Topics: Adrenergic Uptake Inhibitors; Animals; Ankle Joint; Dopamine Agents; Dopamine Antagonists; Drug Comb | 2001 |
Acute and chronic haloperidol treatments increase parkin mRNA levels in the rat brain.
Topics: Animals; Brain; Brain Chemistry; Cell Cycle Proteins; Dopamine Antagonists; Drug Administration Sche | 2001 |
Analysis of the metabolism of haloperidol and its neurotoxic pyridinium metabolite in patients with drug-induced parkinsonism.
Topics: Adult; Antipsychotic Agents; Chromatography, Liquid; Female; Haloperidol; Humans; Parkinsonian Disor | 2001 |
[Ability of novel non-competitive glutamate receptor blocking agents to weaken motor disorders in animals].
Topics: Animals; Anticonvulsants; Ataxia; Benzene Derivatives; Catalepsy; Cations; Cyclohexanes; Excitatory | 2001 |
A simple method to measure stride length as an index of nigrostriatal dysfunction in mice.
Topics: Animals; Antipsychotic Agents; Benserazide; Convulsants; Corpus Striatum; Dopamine Agents; Dopamine | 2002 |
Tardive dyskinesia model in the common marmoset.
Topics: Animals; Biperiden; Callithrix; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug | 2002 |